Study of SHR2554 for T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have T-cell lymphoma confirmed by a doctor.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You must have had at least one prior treatment for your lymphoma, and it didn't work or stopped working.
- You cannot have taken a histone deacetylase inhibitor (a type of targeted therapy) before.
- Your blood, liver, and kidney tests must be in a normal range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This trial tests an investigational pill (SHR2554) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if the pill can shrink the lymphoma and help control the disease.
This study tests an experimental pill (SHR2554) as maintenance therapy after your first treatment for peripheral T-cell lymphoma has worked. The goal is to see if it helps keep the cancer from coming back.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for people with a type of lymphoma called T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help shrink tumors or stop the cancer from growing.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Hear when a new Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.